List of Excipients in Branded Drug ODACTRA

ODACTRA Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

ODACTRA is a differentiated sublingual immunotherapy tablet whose excipient strategy prioritizes rapid oral disintegration, stability of allergen extracts, acceptable mouthfeel, and low moisture exposure. The approved formulation uses mannitol, gelatin, lactose monohydrate, and sodium hydroxide. The strongest commercial opportunities are in allergen-extract tableting, low-moisture oral dosage manufacturing, alternative excipient systems, packaging, and follow-on sublingual immunotherapy products.

What excipients are used in ODACTRA?

ODACTRA contains standardized house dust mite allergen extract in a sublingual tablet. The FDA label identifies four inactive ingredients:

Excipient	Likely formulation function	Commercial relevance
Mannitol	Bulking agent, mouthfeel modifier, rapid-dissolution support	High-volume direct-compression and orally disintegrating-tablet grade opportunity
Gelatin	Matrix-forming and structural excipient; supports lyophilized or rapidly dispersing tablet architecture	Animal-origin compliance, supply qualification, and alternative polymer opportunity
Lactose monohydrate	Bulking agent and compressibility aid	Established pharmaceutical excipient with broad supplier competition
Sodium hydroxide	pH adjustment and manufacturing-process control	Low-volume, specification-sensitive component

ODACTRA is administered once daily under the tongue and is designed to disintegrate in the oral cavity without conventional swallowing. The formulation therefore has different priorities from a standard immediate-release tablet. Rapid wetting, low residual moisture, mechanical integrity, taste control, and allergen stability are central performance attributes (U.S. Food and Drug Administration [FDA], 2017).

How does the ODACTRA formulation work?

The product combines allergen extract with a fast-dispersing tablet matrix. Mannitol provides bulk and a cooling oral sensation, while gelatin can contribute to tablet structure and rapid dispersion. Lactose supports tablet mass and processability. Sodium hydroxide adjusts formulation pH during manufacture.

The formulation must balance competing requirements:

1. The tablet must remain intact during packaging, shipping, and handling.
2. It must disperse rapidly after placement under the tongue.
3. The allergen proteins must retain biological activity over shelf life.
4. The product must have acceptable taste and mouthfeel.
5. Moisture uptake must remain controlled because both tablet mechanics and protein stability can be moisture-sensitive.

The inactive ingredients are therefore part of the product’s delivery platform, not merely low-cost fillers.

What excipient strategy does ODACTRA use?

Rapid-disintegration strategy

Mannitol is a common choice for orally disintegrating and sublingual dosage forms because it provides a relatively clean mouthfeel, low hygroscopicity compared with some polyols, and compatibility with direct compression or freeze-drying processes. Its cooling sensation can reduce the perception of unpleasant taste, although it can also contribute to a distinctive mouthfeel at higher concentrations.

Gelatin supports a porous or rapidly dispersing matrix. In a sublingual allergen tablet, the polymer can help create a unit that is strong enough for packaging but breaks down quickly in saliva.

Protein-preservation strategy

ODACTRA contains biologically active allergen proteins. Excipients must be selected to minimize degradation caused by moisture, temperature, oxidation, pH shifts, and interfacial stress. The formulation does not rely on a conventional surfactant-heavy system. That limits the number of excipient variables but places greater importance on drying, blending, compression, and packaging controls.

Lactose can participate in reducing-sugar reactions with proteins under certain conditions. Its use in ODACTRA means that moisture and temperature control, impurity specifications, and stability monitoring are commercially important. Suppliers offering low-impurity, tightly controlled pharmaceutical lactose may have an advantage in allergen and protein-containing oral products.

Taste and patient adherence

Sublingual immunotherapy is taken daily over a prolonged treatment period. Taste and oral sensation can influence adherence. Mannitol may improve mouthfeel, but the allergen extract itself can produce a characteristic taste. The approved product does not list a separate flavoring system in the FDA prescribing information.

This creates a formulation opportunity for future products using taste-masking approaches that do not impair allergen release or protein stability. Potential approaches include:

• Alternative polyols with controlled cooling effects.
• Low-level sweeteners compatible with allergen proteins.
• Polymer matrices that reduce immediate exposure of bitter or astringent components.
• Microenvironmental pH control.
• Co-processing methods that improve dispersion without adding large excipient loads.

Any modification would need to preserve the immunological dose and bioactivity of the allergen extract.

What commercial opportunities exist for excipient suppliers?

Which excipients have the strongest supply opportunity?

The largest addressable opportunity is likely in pharmaceutical-grade mannitol and specialty tableting systems rather than sodium hydroxide. Mannitol is used at meaningful formulation quantities and can be supplied in grades optimized for direct compression, spray drying, or orally disintegrating tablets.

Commercially relevant product attributes include:

Attribute	Why it matters for ODACTRA-type products
Particle-size distribution	Controls flow, blend uniformity, and compression
Specific surface area	Affects wetting and disintegration
Residual moisture	Influences allergen stability and tablet strength
Compactability	Supports low-force compression and rapid breakup
Microbial quality	Important for oral dosage manufacturing
Trace metals and peroxides	Relevant to protein stability
Lot-to-lot consistency	Supports dose uniformity for biological extracts

Specialty mannitol suppliers can compete through technical data packages, formulation support, and validated grades rather than through price alone.

What opportunities exist for gelatin suppliers?

Gelatin has a more specialized opportunity profile. Suppliers can differentiate through:

• Bovine, porcine, or fish origin.
• Halal and kosher certification.
• Traceability and transmissible spongiform encephalopathy controls.
• Low endotoxin and low bioburden grades.
• Consistent gel strength and viscosity.
• Documentation supporting global regulatory filings.

Gelatin’s animal origin creates a substitution opportunity. Plant-derived polymers, modified celluloses, pullulan, alginates, and synthetic matrix-forming polymers could support products aimed at vegetarian, vegan, religious, or market-specific requirements. A substitute would need to match gelatin’s rapid disintegration and mechanical behavior while avoiding adverse effects on allergen potency.

What opportunities exist for lactose suppliers?

Lactose is a mature and competitive excipient category. The opportunity is strongest in high-purity, low-moisture, low-endotoxin, and tightly characterized grades. Suppliers may also offer lactose alternatives for products targeting lactose-sensitive patients or formulations with greater protein-stability constraints.

Potential substitutes include:

• Mannitol or other polyols.
• Microcrystalline cellulose.
• Trehalose.
• Isomalt.
• Co-processed excipient systems.

The commercial value of substitution depends on whether the alternative improves stability, taste, manufacturability, or market access. Replacing lactose solely to change the inactive-ingredient profile may not justify the regulatory and stability burden.

What formulation patents protect ODACTRA-type products?

ODACTRA’s commercial protection is likely to depend on a combination of product-specific regulatory exclusivity, formulation and manufacturing patents, trademark protection, and know-how. The relevant intellectual-property categories include:

• Sublingual tablets containing house dust mite allergen extracts.
• Specific allergen dosing and standardization methods.
• Rapidly disintegrating or lyophilized oral tablets.
• Excipient matrices using polyols, gelatin, sugars, or polymers.
• Moisture-controlled packaging.
• Manufacturing processes that preserve allergen potency.
• Methods of treating allergic rhinitis or asthma with standardized allergen extracts.

The excipient composition alone may provide limited protection if the formulation uses well-known materials such as mannitol, gelatin, and lactose. Stronger protection generally comes from a defined combination of excipient ratios, physical properties, manufacturing parameters, allergen potency, and performance requirements.

A competitor could attempt a design-around by changing:

• The polymer matrix.
• The bulking agent.
• The drying process.
• The tablet architecture.
• The allergen standardization method.
• The packaging system.

Whether such a product avoids infringement would depend on the scope and construction of issued claims. Public FDA product labeling should not be treated as a complete patent register.

When does ODACTRA lose exclusivity?

ODACTRA was approved by FDA in 2017 under NDA 141242 for house dust mite sublingual immunotherapy in patients aged 12 through 65 years with house dust mite-induced allergic rhinitis, with or without conjunctivitis (FDA, 2017).

Milestone	Date or status
FDA approval	March 2017
Product type	Prescription sublingual allergen immunotherapy tablet
Active ingredient	House dust mite allergen extract
NDA	141242
Conventional small-molecule generic pathway	Not a straightforward assumption
Biosimilar pathway	Not applicable in the conventional monoclonal-antibody sense
Orange Book analysis	Must be assessed against current FDA listing and patent data
Commercial exclusivity end	Depends on statutory exclusivity and enforceable patent rights

ODACTRA is not a conventional small-molecule drug for which a standard ANDA substitution analysis provides the entire competitive framework. Allergen extracts are biologically derived products with complex standardization and potency issues. A follow-on manufacturer may need to address clinical comparability, allergen characterization, manufacturing consistency, and regulatory classification in addition to formulation and patent barriers.

What is the Orange Book status of ODACTRA?

ODACTRA is an FDA-approved prescription product, but its competitive analysis should not rely solely on the Orange Book. Orange Book listings are most useful for identifying approved drug products, listed patents, and regulatory exclusivity where applicable. They do not capture every patent, manufacturing right, trade secret, supplier agreement, or formulation know-how asset relevant to an allergen extract product.

The principal commercial questions are:

• Whether ODACTRA has listed patents in the current Orange Book.
• Whether a competing applicant can file an ANDA or must use another FDA pathway.
• Whether any listed patent creates a Paragraph IV litigation risk.
• Whether the applicant can establish pharmaceutical equivalence and comparable allergen potency.
• Whether the product’s manufacturing process is sufficiently reproducible for approval.

A Paragraph IV challenge would be more complex than a standard tablet challenge because a competitor would need to address both intellectual-property claims and the scientific comparability of a standardized allergen extract.

Are biosimilars or generics a risk to ODACTRA?

Traditional biosimilar risk is low in the conventional sense because ODACTRA is not a monoclonal antibody or recombinant protein product approved through the typical biologics framework. Traditional generic risk is also constrained by the complexity of allergen extracts and sublingual immunotherapy manufacturing.

The more realistic competitive risks are:

1. A competing house dust mite sublingual tablet.
2. A different house dust mite immunotherapy product.
3. Subcutaneous allergen immunotherapy.
4. Alternative sublingual tablets or drops.
5. A product with improved dosing convenience or broader age labeling.
6. A formulation with better taste or fewer animal-derived excipients.

The regulatory barrier is meaningful because allergen extracts require consistent source material, potency assays, impurity control, and clinical performance. The barrier is not absolute. Established allergy-immunotherapy manufacturers with extract standardization capabilities may be better positioned than conventional generic-drug companies.

Which companies compete with ODACTRA?

ALK-Abelló is the principal commercial company associated with ODACTRA. Competitive pressure comes from several groups:

Competitor group	Examples of competitive products or capabilities	Risk to ODACTRA
Sublingual tablet manufacturers	Producers of grass, ragweed, and mite immunotherapy tablets	High strategic relevance
Allergen extract companies	Companies with standardized mite, pollen, and animal dander extracts	High manufacturing relevance
Allergy clinics and specialty providers	Providers using subcutaneous or sublingual immunotherapy	Moderate substitution risk
Generic manufacturers	Companies with oral solid-dose capabilities	Limited without allergen-extract expertise
Excipient and CDMO suppliers	Firms supplying rapid-disintegration platforms	Indirect formulation and licensing opportunity

The most credible competitors are companies that already control allergen source qualification, potency assays, clinical-development expertise, and regulatory relationships.

What excipient licensing and CDMO opportunities exist?

Commercial opportunities can arise through licensing rather than direct ingredient sales. An excipient supplier or CDMO could offer:

• A proprietary sublingual tablet platform.
• A non-gelatin rapid-disintegration matrix.
• A moisture-resistant blister-packaging system.
• A co-processed mannitol-polymer excipient.
• Low-temperature manufacturing for protein-containing tablets.
• Analytical methods for allergen potency and content uniformity.
• Scale-up services for allergen extract blending and compression.

The most defensible platform would combine composition claims with process and performance claims. A generic claim to “a sublingual tablet containing allergen extract and mannitol” would face substantial prior-art exposure. A narrower platform defined by disintegration time, residual moisture, allergen recovery, dose uniformity, and long-term stability could provide stronger commercial differentiation.

What manufacturing and IP barriers affect ODACTRA competitors?

Manufacturing barriers are more important than the cost of common excipients. Key barriers include:

• Standardization of house dust mite source material.
• Control of allergen potency across lots.
• Uniform blending of a biologically active extract at low dose.
• Protection against moisture during tableting and packaging.
• Validation of rapid disintegration without potency loss.
• Long-term stability testing.
• Control of microbial and adventitious-agent risks.
• Reproducible analytical assays.

The excipient supply chain is manageable, but the integrated process is difficult to reproduce. A competitor with the same excipients would not necessarily have the same allergen recovery, tablet performance, or clinical comparability.

How strong is the ODACTRA patent estate?

The estate should be viewed as moderate to strong at the product-platform level, subject to claim scope, expiration, prosecution history, and litigation outcomes. Common excipients provide limited standalone protection. The stronger assets are likely to be claims directed to:

• Standardized allergen combinations.
• Dose and potency parameters.
• Sublingual delivery.
• Specific tablet structures.
• Manufacturing and stabilization methods.
• Treatment regimens.

The estate’s practical strength depends on whether a competitor can produce a clinically acceptable product through a different excipient system and manufacturing route. A design-around using another matrix former or bulking agent could reduce formulation-patent exposure but would not eliminate regulatory and clinical barriers.

What is the commercial opportunity in ODACTRA excipients?

The opportunity is concentrated in enabling technologies rather than commodity ingredient supply.

Opportunity	Commercial attractiveness	Main barrier
Direct-compression mannitol	High	Supplier qualification and price competition
Low-moisture excipient systems	High	Stability validation
Non-gelatin sublingual matrix	High	Performance matching
Protein-compatible lactose alternatives	Moderate	Reformulation and clinical comparability
Allergen tablet CDMO services	High	Specialized manufacturing controls
Moisture-barrier packaging	High	Integration with shelf-life claims
Taste-masking systems	Moderate to high	Allergen-release and safety constraints
Sodium hydroxide supply	Low	Commodity economics

Key Takeaways

• ODACTRA uses mannitol, gelatin, lactose monohydrate, and sodium hydroxide as inactive ingredients.
• Mannitol and rapid-disintegration platforms offer the clearest excipient-supplier opportunities.
• Gelatin creates a market opening for halal, kosher, fish-derived, and plant-based alternatives.
• Lactose is commercially mature, but low-moisture and high-purity grades remain relevant.
• The main competitive barrier is standardized allergen manufacturing, not access to common excipients.
• Conventional biosimilar risk is limited; follow-on allergen tablets and alternative immunotherapy products are more relevant.
• A strong follow-on product would need differentiated allergen potency, stability, taste, manufacturability, and regulatory evidence.
• Excipient patents alone are unlikely to provide broad protection. Process, performance, and allergen-standardization claims are more defensible.
• CDMO services, proprietary sublingual matrices, and moisture-control systems may offer greater value than commodity excipient sales.

FAQs About ODACTRA Excipient Commercialization

Can ODACTRA be reformulated without gelatin?

Yes, but a replacement must match gelatin’s contribution to tablet structure, rapid dispersion, stability, and manufacturability. A non-gelatin formulation would require comparative stability, dissolution or disintegration, potency, and clinical-support data.

Is mannitol the most important excipient in ODACTRA?

Mannitol is likely the most commercially relevant excipient because of its role in tablet bulk, mouthfeel, and rapid dispersion. Its importance depends on the manufacturing process and the quantitative composition of the tablet.

Does lactose in ODACTRA create a patient-access issue?

The product contains lactose monohydrate, but the clinical relevance depends on the amount per tablet and individual patient sensitivity. Lactose-free alternatives could support differentiated products, though substitution would require reformulation and regulatory validation.

Could a generic manufacturer copy ODACTRA’s excipients?

A competitor could potentially use similar excipients, but copying the inactive-ingredient list would not establish equivalent allergen potency, stability, clinical performance, or regulatory acceptability. Patent and regulatory analysis would remain necessary.

What is the best licensing target in the ODACTRA formulation space?

The strongest licensing targets are likely to be proprietary rapid-disintegration matrices, non-animal-origin polymers, low-moisture processing technologies, allergen-compatible taste-masking systems, and validated manufacturing platforms.

References

1. U.S. Food and Drug Administration. (2017). ODACTRA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/141242s000lbl.pdf

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2020). Allergenic extracts: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/allergenic-extracts

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: ODACTRA, NDA 141242. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

5. World Health Organization. (2009). WHO guideline on stability evaluation of vaccines and related biological products. World Health Organization. https://www.who.int/publications/m/item/WHO-IVB-06.20